Taking advantage of their immunomodulatory functions, several clinical trials in melanoma, RCC, NSCLC and hepatocellular carcinoma have successfully evaluated the combination of checkpoint inhibition with VEGF/VEGFR blockade, providing evidence of the efficacy of such an approach. The gene discussed is KDR; the disease is renal cell carcinoma.